Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.
Price history
Loading SCNX daily closes…
Loading price history…
Pipeline assets
Arbli
Approved · Active
Aliases SCN-102
Target Angiotensin II receptor (AT1)
Indications
Hypertension(Approved)
Stroke risk reduction in hypertension with left ventricular hypertrophy(Approved)
Diabetic nephropathy in type 2 diabetes(Approved)
Status note One of the Company's two launched commercial products; FDA approved in the first quarter of 2025. Indication not stated in the excerpts.
REZENOPY
Approved · Active
Target opioid receptor
Indications
Opioid overdose reversal(Approved)
Status note One of the Company's two launched commercial products. Indication not stated in the excerpts.
SCN-106
Stage not disclosed · ActiveModality: biologic (biosimilar)
Target plasminogen
Status note Potential biosimilar based on Cathflo Activase, a reference thrombolytic agent. Stage and indication not stated in the excerpts.
Per-asset detail extracted from the 10-Q filed 2026-05-14. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
No lead program on file for this company.
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
No specialist-fund holders in 13F data for this company.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 714 stocks.